U.S. seeks warnings for Amylin diabetes drug (Reuters)

Reuters - U.S. health regulators warned of more cases of dangerous pancreas inflammation in patients taking Amylin Pharmaceuticals Inc's diabetes drug, Byetta, pounding company shares on fears of lower sales and doubts about a new version of the medicine.